268 related articles for article (PubMed ID: 15041377)
1. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
5. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
[TBL] [Abstract][Full Text] [Related]
6. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
7. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
Konstadinidou I; Boletis JN
Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
[TBL] [Abstract][Full Text] [Related]
8. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
Cole E; Deshpande R
Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
[TBL] [Abstract][Full Text] [Related]
9. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
10. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
Bunnag S; Vareesangthip K; Ong-ajyooth L
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
[TBL] [Abstract][Full Text] [Related]
11. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
Lück R; Böger J; Kuse E; Klempnauer J; Nashan B
Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic monitoring and outcomes of cyclosporine.
Pollard SG
Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
[TBL] [Abstract][Full Text] [Related]
15. Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation.
Furlan V; Lykavieris P; Maubert MA; Habes D; Debray D
Transplant Proc; 2009 Oct; 41(8):3333-4. PubMed ID: 19857744
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
[TBL] [Abstract][Full Text] [Related]
17. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
Troncoso P; Ortiz AM; Jara A; Vilches S
Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of cyclosporine.
Midtvedt K
Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan.
Chou NK; Chen RJ; Ko WJ; Lin HL; Yu SY; Chen YS; Hsu RB; Lee CM; Lin FY; Wang SS
Transplant Proc; 2004 Oct; 36(8):2393-5. PubMed ID: 15561260
[TBL] [Abstract][Full Text] [Related]
20. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients?
Marin JG; Levine M; Ensom MH
Ther Drug Monit; 2006 Oct; 28(5):637-42. PubMed ID: 17038878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]